Benign paroxysmal positional vertigo – another benefit of vitamin D

September 16, 2020

Vitamin D deficiency predisposes to or worsens many different medical problems. I’ve written at least a dozen blog posts on vitamin D.

A group of South Korean researchers just published in the journal Neurology a study, Prevention of benign paroxysmal positional vertigo with vitamin D supplementation. A randomized trial.

They selected 518 patients with confirmed BPPV who were successfully treated with canalith repositioning maneuvers (Epley maneuver) and who had a vitamin D level below 20. The primary outcome measure was the annual recurrence rate. Patients in the intervention group were given vitamin D 400 IU and 500 mg of calcium carbonate twice a day for 1 year. Patients in the observation group were assigned to follow-ups without further vitamin D evaluation or supplementation.

The intervention group had a significant reduction in the treatment group compared to the observation group.

The authors concluded that supplementation of vitamin D and calcium may be considered in patients with frequent attacks of BPPV, especially when serum vitamin D is subnormal.

BPPV, dizziness, vertigo, difficulty with balance are more common in people with migraines. Keeping your vitamin D level at least in the middle of the normal range may help prevent all these symptoms as well as migraines and other neurological problems.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe